Table 2 Adjusted multivariable analysis of TAT and muscle ratios. Adjusted mean difference (pre/post ETI therapy) shown for pwCF who were initially categorized as underweight (n = 20) versus normal- + overweight (n = 41 + 5 = 46).

From: Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis

Post versus Pre-ETI

Adjusted mean difference (95%CI)

p-value

Muscle ratio

 Interaction time (pre/post)*BMI category

 

0.925

 For BMI underweight

0.072 (− 0.112, 0.255)

0.694

 For BMI normal-/overw

0.061 (− 0.151, 0.273)

0.847

 Age at ETI start, years

− 0.020 (− 0.024, − 0.015)

0.397

 Biological sex, male

0.323 (0.211, 0.435)

< 0.001

 ETI therapy, months

0.011 (0.005, 0.017)

< 0.001

TAT ratio

 Interaction time (pre/post)*BMI category

 

0.013

 For BMI underweight

0.831 (0.489, 1.173)

< 0.001

 For BMI normal-/overw

0.330 (− 0.097, 0.758)

0.174

 Age at ETI start, years

− 0.010 (− 0.020, 0.000)

0.053

 Biological sex, male

− 0.740 (− 0.987, − 0.493)

< 0.001

 ETI therapy, months

0.003 (− 0.011, 0.017)

0.659

SAT ratio

 Interaction time (pre/post)*BMI category

 

0.019

 For BMI underweight

0.647 (0.349, 0.944)

< 0.001

 For BMI normal-/overw

0.240 (− 0.135, 0.616)

0.315

 Age at ETI start, years

− 0.009 (− 0.017, − 0.001)

0.039

 Biological sex, male

− 0.701 (− 0.917, − 0.485)

< 0.001

 ETI therapy, months

0.002 (− 0.009, 0.013)

0.640

IMAT ratio

 Interaction time (pre/post)*BMI category

 

0.025

 For BMI underweight

0.125 (0.078, 0.173)

< 0.001

 For BMI normal-/overw

0.062 (0.008, 0.116)

0.020

 Age at ETI start, years

− 0.002 (− 0.003, − 0.001)

0.024

 Biological sex, male

− 0.061 (− 0.092, − 0.030)

< 0.001

 ETI therapy, months

0.001 (− 0.001, 0.003)

0.227

EAT ratio

 Interaction time (pre/post)*BMI category

 

0.131

 For BMI underweight

0.019 (0.006, 0.032)

0.002

 For BMI normal-/overw

0.008 (− 0.001, 0,018)

0.111

 Age at ETI start, years

− 7.84e−5 (− 3.61e−4, 2.04e−4)

0.587

 Biological sex, male

− 0.001 (− 0.008, 0.006)

0.833

 ETI therapy, months

− 1.21e−4 (− 4,79e−4, 2.38e−4)

0.681

PAT ratio

 Interaction time (pre/post)*BMI category

 

0.155

 For BMI underweight

0.040 (0.014, 0.066)

0.001

 For BMI normal-/overw

0.020 (− 0.004, 0.043)

0.134

 Age at ETI start, years

− 0.001 (− 0.001, 0.000)

0.165

 Biological sex, male

0.022 (0.008, 0.036)

0.002

 ETI therapy, months

− 8.59e−4 (− 0.002, 9.75e−5)

0.078

  1. Statistics: Values are estimates (95% confidence interval) calculated using generalized estimating equation models (GEE) for pre/post ETI outcome variables. CI, confidence interval; TAT, total adipose tissue; IMAT, intra- and intermuscular adipose tissue; EAT, epicardial adipose tissue; PAT, paracardial adipose tissue; SAT, subcutaneous adipose tissue. Bold text: Adjusted mean differences for pwCF with underweight versus normal/overweight BMI category.
Back to article page